Gavi’s board revised its strategy for the next five years in light of a $3 billion funding gap. This follows shortfalls at its high-level fundraising event last month in Brussels, where the organization raised between $9.5 billion and $10.5 billion — short of its $11.9 billion to $13 billion target.
During the event, U.S. Health Secretary Robert F. Kennedy Jr. announced the U.S. is cutting its support to Gavi, the Vaccine Alliance, after months of uncertainty.
As part of the revised strategy, the board approved a new approach to supporting children living in fragile and humanitarian contexts, confirmed it will introduce respiratory syncytial virus, or RSV, vaccines for pregnant mothers, and approved the creation of an mpox vaccine stockpile.
About the author
Sara Jervingsarajerving
Sara Jerving is a Senior Reporter at Devex, where she covers global health. Her work has appeared in The New York Times, the Los Angeles Times, The Wall Street Journal, VICE News, and Bloomberg News among others. Sara holds a master's degree from Columbia University Graduate School of Journalism where she was a Lorana Sullivan fellow. She was a finalist for One World Media's Digital Media Award in 2021; a finalist for the Livingston Award for Young Journalists in 2018; and she was part of a VICE News Tonight on HBO team that received an Emmy nomination in 2018. She received the Philip Greer Memorial Award from Columbia University Graduate School of Journalism in 2014.
